Growing Human Brains in Space

Growing Human Brains in Space

University of California Television (UCTV)

0:19 Alysson Muotri: I'll share a little bit of the work that we do in the lab,

0:23 basically sending brain tissues or brain organoids to space,

0:28 and there is a reason for that.

0:30 My lab focus on neurological conditions.

0:33 Most of them neurogenetic conditions such as autism.

0:37 You are born with autism.

0:40 You don't get autism after you are born.

0:43 Everything happens in uterus, inside the uterus,

0:48 and this inaccessibility of the brain tissue is one

0:51 of the things that makes the sign so hard.

0:54 It's different from cancer, from heart, from blood, where you can have biopsies.

1:00 You can see what's happening.

1:01 In the brain, it starts in uterus and keeps inside that is core to your life.

1:08 Really hard to study.

1:10 Despite the fact that we know

1:12 that these conditions have a strong genetic factor,

1:16 we don't know exactly how the genes plays into behavior and neuroscience.

1:20 The interface between the genetics and neurobiology,

1:24 that's exactly where my lab is.

1:27 We start developing tools to actually create

1:31 better models to understand the human brain.

1:34 As I mentioned, because this always starts in uterus so I turn into stem cells.

1:40 That's when the brain tissue start to become what we have today in our heads.

1:46 It always start with stem cells.

1:48 I was inspired by the first observation that stem cells when growing suspension

1:54 and neutralize can form these clusters

1:56 of cells that we now call brain organoids.

2:00 Over the years, my lab have been improving

2:03 these protocols to create something that is more robust, cheaper,

2:07 easy accessibility, and also a protocol that produces neurons

2:13 that can fire and connect to each other forming networks.

2:17 This is an example of what we call a semi-guided brain organoid where we

2:21 transiently expose progenitor cells to specific factors

2:26 that guide the cells towards the cortical tissue.

2:28 It's a simple protocol where you neuralize the pluripotent stem cells.

2:33 Again, in suspension induce the proliferation

2:35 of the precursor cells, and afterwards,

2:38 you just withdraw these factors and the cells will mature over time,

2:41 forming these spheres that contains about five million cells,

2:45 2.5 million neurons in each one of them.

2:48 If you've never seen one, this is how we grow them in these six well dishes.

2:53 Each one of these white dot is the beginning of a brain

2:56 organoid that will grow up to 2.5 centimeter in diameter.

3:00 The cool thing about these organoids is

3:02 that you can measure the electrical activity,

3:05 and we have been following how these networks rearrange and connect over a year,

3:11 and this is more or less what we learned that it

3:13 takes about two months for them to have a robust electrical activity.

3:18 Before that, you can see neurons firing,

3:20 but they are not connecting to each other.

3:22 They're just firing in a random fashion.

3:25 After two months, they start to get organized and start

3:28 to form some circuitries that might generate what we call neural oscillation.

3:33 These neural oscillations will develop through the next month or two,

3:38 and will become quite robust and stereotype.

3:42 After that, these oscillations will become more complex over time,

3:47 and this is all due to the emergency

3:49 of specific cell types in this population such

3:52 as astrocytes that helps with the synaptogenesis

3:55 or inhibitory neurons that help to modulate this network.

4:00 The cool part of this model is that it

4:02 recapitulates the early stages of neurodevelopment quite well.

4:06 Even the timing it's quite well reproduced in our dishes.

4:13 It takes about nine months for the human

4:16 brain to start showing these complex neural oscillation.

4:21 The model is perfect to study conditions such as autism.

4:25 The problem is that we don't want to just focus on the preembryonic stages,

4:31 but we want to also understand what happens

4:33 when our brains are 1, 2, 10, 9-years-old.

4:36 We start getting into the age factor of the model,

4:41 which is not currently possible.

4:43 I was looking to ways of doing that.

4:46 How can I speed up?

4:48 How can I accelerate neurodevelopment in the lab,

4:51 and that's when I came across some of the NASA literature suggesting that cells

4:56 from the astronauts returning from the space

5:00 actually show signs of accelerated senescence,

5:03 something that might be seen as an accelerated aging,

5:06 and even more importantly, signs of cognitive decline has also been reported,

5:12 and this cognitive decline cannot be fully

5:16 restored even six months after the flights.

5:19 This is also a concern for long flights into space,

5:24 but we can actually think about leveraging

5:27 this phenomenon here to earth to understand age-related conditions.

5:32 Starting in 2019, we actually have several missions to the International Space

5:38 Station by sending brain organoids

5:40 in an autonomous platform together with Space Tango,

5:45 our implementational partners.

5:47 These organoids have specific payloads that changes the media,

5:52 keep them alive in a similar way as we would do it here.

5:55 Because these platforms are quite autonomous,

5:58 the astronaut doesn't need to do too much.

6:02 Basically plug these boxes inside the cabinets in there,

6:07 and then we have immediately access to the experiments inside.

6:11 What did we learn with these experiments?

6:14 Most of the experiments are kept

6:17 at the International Space Station for about 30 days.

6:21 Upon their return, what we learned was that some

6:25 of the cells show signs of cellulated aging or extreme maturation,

6:31 and this is seen in the transcriptomics.

6:34 This is just comparing space and ground controls.

6:37 Several molecular pathways related to senescence is also highlighted.

6:43 On the proteomic side, this was done by Lynn and Paolo at the Ice Core,

6:48 where they compare the overall proteomic changes

6:51 that happens after these 30 days in space,

6:54 reaching a specific age of about 10-12 years on average.

7:00 Thirty days in space when the cells return,

7:03 they'll have a proteomic profile of a neuron or a brain

7:07 cell that is equivalent of a 10, 12-year-old person.

7:11 Moreover, on the proteomics,

7:13 we can also take advantage of single cell proteomics to understand

7:17 different cell populations and what happens inside each one of these cells.

7:22 So complicated is lies, and I believe Aline might detail this more.

7:26 But again, I mean, we see several

7:29 molecular pathways that are age related conditions,

7:33 increasing some pathoys that are quite interesting,

7:36 for example, the derepression of retro elements.

7:39 These are endogenous retrovirus inside the genome.

7:43 But also mitochondria is affected.

7:45 Oncogenes, your telomeres are affected.

7:49 Several of these molecular pathways that we see only in more adult,

7:55 older postmortem tissues.

7:57 Even more importantly,

7:58 once these cells return or the brain organoids return to earth,

8:03 we can actually measure the electrical activity

8:06 by placing them on top of multi electrode array.

8:09 What we are learning is that over time, different from the ground control,

8:14 there is indications that the networks start to get fragmented.

8:20 Instead of starting getting more connected as you would expect,

8:24 if a linear development here on Earth, we see fragmentation of the network,

8:30 something that will be related to dementia or an Alzheimer's network.

8:36 Is there any useful of all this information?

8:39 In one of those missions,

8:41 we start sending patient derived brain organoids to space,

8:44 and we start with Rett syndrome is a neurological

8:47 condition that I have been studying for a while.

8:50 It's quite severe.

8:51 The kids develop quite normal for the first 18 months.

8:55 You even didn't notice that there is a problem there.

8:58 But after that, there is a decline

9:01 and the kids start losing their motor abilities, their verbal capabilities,

9:06 basically all their skills,

9:08 and end up in a wheelchair for the rest of their life.

9:12 What happens in these 18 months that the system their brains crash.

9:17 We don't have good models for that.

9:19 I told you that the brain

9:21 organoid model just recapitulated the pre-embryonic phase,

9:24 and the mouse model doesn't survive that long.

9:27 We really don't know what happens to the brain when it reached that stage.

9:32 By sending Rett syndrome brain organoids, we learned something new.

9:35 We learned that brain cells, specifically glia cells or astrocytes

9:40 from the organoids accumulate the endogenous

9:43 retrovirus that I mentioned to you that has been related to aging.

9:47 The accumulation of the retrovirus leads to an increase in inflammation.

9:52 Rett syndrome was never proposed to be an inflammatory condition,

9:56 so it's only in this model that we could

9:58 actually see elevation of certain cytokines such as IL-6.

10:03 If the accumulation of endogenous retrovirus is related to aging,

10:08 there's tons of evidence in the literature

10:11 indicating that these specifically line elements

10:15 could actually accumulate in the cytoplasm

10:18 and trigger some of these pro-inflammatory pathways.

10:22 If we were able to target that using reverse-transcriptase inhibitors,

10:27 for example, antiretroviral drugs, perhaps we could eliminate the inflammation

10:33 and help with the brains with Rett syndrome.

10:36 Sounds weird treating a neurological condition with an antiretroviral,

10:41 HIV drugs that are already FDA approved, cheap drugs.

10:45 I mean, would that be possible?

10:47 Then we turn back into our preclinical models

10:52 here on Earth both mouse and human models.

10:57 I'll show you just one example of the mouse models here,

11:03 where we treat the animals just

11:05 before they die with reverse-transcriptase inhibitors,

11:08 and the animals increase the survival

11:11 and start to reacquiring their motor skills again.

11:14 This was, to the best of our knowledge,

11:18 something that was never seen before for this specific model for Rett syndrome.

11:24 Not only the behavior,

11:27 but we actually see changes in the morphology of the neurons.

11:30 They recapitulate the spine density,

11:32 even the size of the neurons could be restored.

11:35 That was enough for the FDA to approve the clinical

11:40 trial for Rett syndrome and we start treating these patients.

11:45 Hopefully, in six months from now, we're going to know if antiretrovirals are

11:49 useful for the treatment of Rett syndrome.

11:52 But what about age related conditions more towards the end of your life,

11:58 such as Alzheimer's and dementia?

12:00 This is a big market, and we also wanted to focus on that.

12:03 We have a postdoc in the lab that is focusing on Alzheimer's.

12:08 That's Natalia Sherman.

12:09 She's been sending brain organoids derived

12:12 from Alzheimer's to the space station.

12:14 Again, I will not give you too much details here,

12:17 but just to say that there are specific pathways,

12:20 especially related to the synopsis that seems

12:23 to be affected in Alzheimer's disease.

12:25 We are still trying to understand how these networks are affected.

12:29 But nonetheless, having a model

12:31 for Alzheimer's is really helpful because, again,

12:33 I mean, where would you get older human neurons to test potential treatments?

12:39 There is no model for Alzheimer's.

12:42 We think that this might be like

12:43 a value opportunity for us to test potential therapeutics.

12:47 I decided to team up with the largest pharmaceutic in the world,

12:53 which is my friends in the Amazon.

12:57 In the Amazon, there is about 300,000 species in there,

13:01 and certain plants do contain neuroactives

13:04 that has never been studied by modern science.

13:07 The idea was team up with the original tribes and search

13:14 for their ancestral knowledge to find what are the plants.

13:18 I'll play a quick video that illustrate more or less how this is done.

13:22 We start by the identification of these plants.

13:26 Again, in collaboration with these original tribes,

13:29 they point us to the plants that might be neuroprotective for the human brain.

13:35 They have been using this for thousands of years, actually.

13:41 Some of these plants are not so easy to get.

13:43 They are embedded inside of the Amazon.

13:46 To do that, we create a specific AI to inside

13:51 a little robot that contains the ancestral knowledge of the Shamans.

13:55 It's a visual system.

13:57 These little robots, you're going to see in a moment,

14:00 can actually fly through the forest and identify the specific

14:05 plants that we can send like someone to collect.

14:08 Someone from the tribes will go there, collect the plants,

14:11 replant more, and bring it back to the lab.

14:14 Once in the lab, we can isolate the extract

14:18 and using a several AI type of pipeline,

14:21 which would take thousands of years to do it five years ago,

14:26 now we can do it in a week.

14:28 We can actually point to specific molecules

14:31 that can bind to specific neuronal receptors.

14:33 We are scoring these molecules.

14:36 This would be the first candidate to travel to space

14:40 to actually be tested directly into brain organoids over there.

14:45 Once we bring the cells back,

14:47 the ones that has been exposed to certain of these molecules,

14:51 if they show reversal of the phenotypes, those are going to be strong

14:57 candidates for potential therapeutics for Alzheimer's,

15:00 dementia, and other neurodegenerative disorders.

15:04 We are also working better ways to visualize the activity of the neurons,

15:09 working with fluorescent markers as well as pathophysiology

15:13 that can be done actually in space.

15:17 We have real time capabilities through the ascending,

15:22 the time in space, and also descending.

15:25 That would be a game changer for us right now,

15:27 we put the organoids in a box, goes to the space, comes back.

15:31 We don't know what happens in between.

15:33 We just know before and after.

15:35 But this time would allow us to actually

15:38 follow the entire trajectory of these organoids.

15:42 I'm finishing here.

15:44 These are basically my take home messages.

15:47 We think that growing these brain organoids in space can

15:51 teach us about the impact of space into human cognition.

15:57 We can accelerate aging and use this as a model

16:01 for aging here on Earth, not only aging,

16:04 but rejuvenation and treatments and can be used to test novel neuroprotective

16:10 molecules or compounds either from Pharma who may have them on their shelves,

16:16 as well as new drugs that has never been discovered before.

16:20 I'll end here by thanking the members of Ice

16:25 Core that participates on that, several of the funding agencies.

16:29 Thank you.

16:30 [APPLAUSE] Speaker 1: Can you tell us a little bit more about

16:35 your clinical trial that you're doing and where that started?

16:39 Alysson Muotri: Yeah.

16:40 Right now because it's FDA approved drug,

16:43 the clinical trial was immediately approved by the FDA.

16:47 We also approved that in Brazil.

16:49 We are starting there in Brazil with a pilot

16:53 experiment that is going to be, I believe,

16:55 13 kids, different ages, and half of them would take placebo,

17:01 half of them would take the real drug.

17:03 There is a doctor that specialize in the milestones of these patients to see

17:09 if we can have either a slow

17:12 progression through these milestones or any reversal.

17:16 Speaker 1: We get to see each other all the time,

17:18 and yet I have so many questions.

17:20 Would it be possible to do some of the preliminary extraction and API,

17:24 active pharmaceutical ingredient development in Brazil closer

17:27 to where the sources for these new compounds?

17:31 Alysson Muotri: Oh, for the new compounds.

17:33 Yeah, absolutely.

17:34 This is something we're thinking about.

17:37 It will depend on the molecule.

17:40 As you know, some of the molecules might be hard to synthesize.

17:43 Speaker 2: Truly inspiring.

17:46 I'm guessing a lot of those compounds that you're screening can

17:50 relate to a lot of neurodegeneration that is related or not,

17:55 maybe to DNA damage and things like that.

17:57 Have you considered also,

18:00 in your screening an AI base to extend it not only to neuroreceptors,

18:06 but maybe other things that we know that maybe we can screen,

18:09 and there are so many people around us that can look,

18:12 oh, that can be actually a super cool candidate.

18:15 Alysson Muotri: Yeah.

18:16 You are absolutely right.

18:17 That's the ultimate goal is to create a catalog where this would be available.

18:22 People can mind that, can see if it works in other cell types.

18:26 Absolutely.

18:26 We are also working with not only isolated molecules, but extracts.

18:32 If we want to start with an extract, might be better chances to find something.

18:36 Then you funnel out a specific molecule.

18:40 Speaker 2: That's beautiful.

18:41 Thank you.

18:42 Speaker 3: I think connected to that, not

18:45 just other cell types or other diseases.

18:48 What about other plants, not just in Amazon, but other areas of the world?

18:53 Alysson Muotri: Yeah.

18:54 Once I start talking about that, other groups start

19:00 to reaching out to reproduce similar things with different ecosystems.

19:05 For example, the Saudis have the coral reefs that are bleaching,

19:11 and before it bleaches, they start collecting bacteria from them and create

19:15 a chemical library from the coral reefs.

19:18 That's another thing that is going to get extinct.

19:21 People will not be able to reproduce that.

19:24 But finally, I mean,

19:25 they save at least a part of that and could be used to screen as well.

19:30 Also, I started working with Bill Panico, who he's retired now,

19:34 but he was from scripts of oceanography here,

19:37 where he isolated bacteria from deep sea,

19:40 also contains lots of molecules that has never been studied before.

19:45 [MUSIC]

Study with Looplines Download Captions Watch on YouTube